Shares of Onconova Therapeutics, Inc. (NASDAQ:ONTX – Get Rating) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.35 and traded as low as $0.95. Onconova Therapeutics shares last traded at $0.97, with a volume of 81,776 shares trading hands.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on shares of Onconova Therapeutics in a report on Friday. They issued a “hold” rating for the company.
Onconova Therapeutics Stock Performance
The firm has a market capitalization of $20.20 million, a PE ratio of -1.26 and a beta of 1.47. The company has a fifty day simple moving average of $1.22 and a two-hundred day simple moving average of $1.35.
Hedge Funds Weigh In On Onconova Therapeutics
A number of hedge funds have recently bought and sold shares of the business. Millennium Management LLC boosted its stake in Onconova Therapeutics by 154.6% during the second quarter. Millennium Management LLC now owns 61,390 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 37,275 shares during the last quarter. Beacon Pointe Advisors LLC raised its position in shares of Onconova Therapeutics by 147.0% during the 1st quarter. Beacon Pointe Advisors LLC now owns 46,027 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 27,396 shares during the period. Finally, Renaissance Technologies LLC grew its position in Onconova Therapeutics by 3.6% in the second quarter. Renaissance Technologies LLC now owns 333,323 shares of the biopharmaceutical company’s stock worth $440,000 after acquiring an additional 11,580 shares during the period. Hedge funds and other institutional investors own 8.83% of the company’s stock.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Onconova Therapeutics (ONTX)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.